外科理论与实践Issue(5)：434-439,6.DOI:10.16139/j.1007-9610.2015.05.016
吉西他滨联合替吉奥方案治疗胰腺癌优于吉西他滨单药的荟萃分析
Combination of gemcitabine and S-1 in the treatment of pancreatic cancer improved efficacy over gemcitabine alone：a meta-analysis
霍震 1沈柏用 1王维 1王新景 1张天 1詹茜 1金佳斌 1陈皓 1邓侠兴 1彭承宏1
作者信息
- 1. 上海交通大学医学院附属瑞金医院外科，上海 200025
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of the combination of gemcitabine (GEM) plus S-1 (GS) versus GEM alone in the treatment of advanced pancreatic cancer. Methods Pertinent studies were identified from the Pubmed, Web of Knowledge and the Cochrane Library. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and grade 3-4 advent events were analyzed. Results Four randomized controlled trial of 871 patients were finally included in this analysis with 432 cases in GEM plus S-1 (GS) group, and 439 cases in GEM group. It was shown by meta-analysis that the significant improvement with GS therapy in OS and PFS over GEM alone ( HR=0.83, 0.65, 95%CI:0.72~0.96, 0.56~0.75, respectively) . GS therapy also exhibited significant advantage in ORR ( OR=3.00, 95%CI:2.04~4.41). Although grade 3-4 advent events including leukopenia, neutropenia, thrombocytopenia, rash, diarrhea, mu-cositis/stomatitis, and nausea/vomiting showed more often in GS group, similar other non-hematological advent events of grade 3-4 were found between two groups. Conclusions GS therapy significantly improved OS, PFS and ORR compared with GEM therapy with acceptable toxicity in patients with unresectable and advanced pancreatic cancer.关键词
胰腺癌/替吉奥/吉西他滨/荟萃分析Key words
Pancreatic cancer/S-1/Gemcitabine/Meta-analysis分类
医药卫生引用本文复制引用
霍震,沈柏用,王维,王新景,张天,詹茜,金佳斌,陈皓,邓侠兴,彭承宏..吉西他滨联合替吉奥方案治疗胰腺癌优于吉西他滨单药的荟萃分析[J].外科理论与实践,2015,(5):434-439,6.
